Table 2. Open in new tab Everolimus...

Table 2.

Everolimus Lowers Plasma Aldosterone Levels in Some PA Patients, Decreases Blood Pressure, and Attenuates Renin Suppression

	V3 (D 0)	V5 (D 15)	V6 (D 28)
Basal plasma aldosterone, pM	640 (504–1054)	668 (468–831)	675 (427–981)
Direct renin concentration, ng/L	0.7 (0.3–1.4)	1.5 (0.7–4.7)^a	0.7 (0.2–3.9)^b
Plasma F, nM	238 (185–267)	214 (166–298)	167 (139–236)^b
ACTH, pg/mL	13.5 (8.4–22.3)	12.0 (6.2–21.8)	14.1 (8.4–19.1)
Copeptin, pM	6 (3.9–8.9)	6 (4.7–9.2)	5.7 (3.4–9.7)
Serum potassium, mM	4.1 (3.7–4.3)	4.0 (3.9–4.2)	3.8 (3.7–4.0)
Potassium substitution, mmol/d	100 (60–140)	120 (60–140)	120 (60–140)
7-Day home blood pressure
Systolic, mm Hg	132 (129–150)	130 (125–140)^b	134 (129–149)
Diastolic, mm Hg	87 (80–94)	84 (78–90)^b	86 (82–95)
Cardiac index, L/min/m²	2.5 (1.6–3.4)	2.7 (2.4–3.3)	2.5 (1.5–2.9)
Heart rate, beats per min	55 (52–68)	61 (54–66)	63 (57–66)

	V3 (D 0)	V5 (D 15)	V6 (D 28)
Basal plasma aldosterone, pM	640 (504–1054)	668 (468–831)	675 (427–981)
Direct renin concentration, ng/L	0.7 (0.3–1.4)	1.5 (0.7–4.7)^a	0.7 (0.2–3.9)^b
Plasma F, nM	238 (185–267)	214 (166–298)	167 (139–236)^b
ACTH, pg/mL	13.5 (8.4–22.3)	12.0 (6.2–21.8)	14.1 (8.4–19.1)
Copeptin, pM	6 (3.9–8.9)	6 (4.7–9.2)	5.7 (3.4–9.7)
Serum potassium, mM	4.1 (3.7–4.3)	4.0 (3.9–4.2)	3.8 (3.7–4.0)
Potassium substitution, mmol/d	100 (60–140)	120 (60–140)	120 (60–140)
7-Day home blood pressure
Systolic, mm Hg	132 (129–150)	130 (125–140)^b	134 (129–149)
Diastolic, mm Hg	87 (80–94)	84 (78–90)^b	86 (82–95)
Cardiac index, L/min/m²	2.5 (1.6–3.4)	2.7 (2.4–3.3)	2.5 (1.5–2.9)
Heart rate, beats per min	55 (52–68)	61 (54–66)	63 (57–66)

Comparison of baseline measurements (V3, day 0) after a 2-wk treatment with everolimus (V5, d 15) and after a 2-wk washout period (V6, d 28). Data are shown with median and IQR.

P < 0.001 vs baseline (Friedman test with Dunnett post hoc test).

P < 0.05.

This Feature Is Available To Subscribers Only